We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

IN8BIO Inc (INAB) USD0.0001

Sell:$1.00 Buy:$1.07 Change: $0.0299 (2.88%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.0299 (2.88%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
Change: $0.0299 (2.88%)
Market closed |  Prices as at close on 24 May 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead program, INB-400, is in a Phase II clinical trial in which autologous, genetically modified gamma-delta T cells are assessed in glioblastoma (GBM). Its additional programs include Phase I trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for the treatment of patients with hematologic malignancies that are undergoing hematopoietic stem cell transplantation (HSCT). In addition, the Company’s DeltEx platform has yielded a portfolio of preclinical programs, including INB-300 and INB-500, focused on addressing acute myeloid leukemia (AML) and other solid and hematological tumor types.

Contact details

Empire State Building
350 5Th Avenue, Suite 5330
United States
+1 (646) 6006438

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$44.57 million
Shares in issue:
44.12 million
United States
US dollar

Key personnel

  • William Ho
    President, Chief Executive Officer, Director
  • Lawrence Lamb
    Co-Founder, Executive Vice President, Chief Scientific Officer
  • Patrick Mccall
    Chief Financial Officer
  • Kate Rochlin
    Chief Operating Officer
  • Trishna Goswami
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.